Results 41 - 50 of 208 : Previous 1 2 3 4 5 6 7 8 9 Next
How You're Going to Beat the Market This Year
It's never too early to get started.
This bullish call comes from more than just one analyst.
Seattle Genetics Has What Others Want
Out-licensing its platform technology could mean big bucks.
The one-drug wonder now becomes a marketer of two compounds.
A Hearteningly Cheap Rule Breaker
Sometimes, even a growth stock goes on sale.
As the FDA Generics Office Turns
The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
A Drug to End Merck's Headache?
Merck presents promising data for its phase 3 migraine drug.
Surprise! The FDA actually approves a new medicine without delay.
WuXi partners with Covance, but is it really a good long-term play?
Is Pfizer ready for a comeback?
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK